Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Quality of Life (QOL)

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   40977   clinical trials with a EudraCT protocol, of which   6698   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,553 result(s) found for: Quality of Life (QOL). Displaying page 1 of 78.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-002484-87 Sponsor Protocol Number: GAST-TaxXel Start Date*: 2005-07-11
    Sponsor Name:Raija Ristamäki
    Full Title: Biweekly Taxotere in combination with Xeloda as first-line treatment in patients with advanced gastric cancer
    Medical condition: advanced gastric cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004835-72 Sponsor Protocol Number: UB-MedSci-001/2004 Start Date*: 2005-01-12
    Sponsor Name:University of Birmingham [...]
    1. University of Birmingham
    2. University Hospital Birmingham Foundation NHS Trust
    Full Title: A study to determine the effects of growth hormone (GH) replacement therapy on quality of life and cardiovascualr risk in GH deficient adults
    Medical condition: Growth hormone deficiency in adult life
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005424-97 Sponsor Protocol Number: CIGE025EFR02 Start Date*: 2015-01-28
    Sponsor Name:NOVARTIS PHARMA SAS
    Full Title: A phase IV, multicenter, single-arm and open-label study to explore the impact on quality of life of omalizumab (Xolair®) in patients with chronic spontaneous urticaria (CSU) who remain symptomatic...
    Medical condition: chronic spontaneous urticaria
    Disease: Version SOC Term Classification Code Term Level
    18.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-001023-39 Sponsor Protocol Number: ML28786 Start Date*: 2013-08-08
    Sponsor Name:Roche Austria GmbH
    Full Title: LISAH: AN OPEN-LABEL, RANDOMISED PHASE II STUDY ASSESSING QUALITY OF LIFE ASSOCIATED WITH SUBCUTANEOUS TRASTUZUMAB INJECTED INTO THE THIGH OR UPPER ARM IN PATIENTS WITH HER2-POSITIVE EARLY BREAST C...
    Medical condition: HER2-positive early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2008-000547-34 Sponsor Protocol Number: QoL-ESC RevMDS Start Date*: 2008-06-09
    Sponsor Name:ASSOCIAZIONE QOL-ONE
    Full Title: Lenalidomide for Myelodysplastic Syndromes: Efficacy, Safety, Cardiac Changes, and Quality of Life (QoL-ESC RevMDS)
    Medical condition: Low or Intermediate-1 IPSS risk MDS with del(5q)as a single or combined cytogenetic abnormality and with anemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003028-59 Sponsor Protocol Number: NL62684.091.17 Start Date*: 2018-06-06
    Sponsor Name:Radboud University Medical Centre
    Full Title: Treatment with Recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with Anaplastic Thyroid Cancer: a proof of concept study
    Medical condition: Anaplastic Thyroid Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005362-19 Sponsor Protocol Number: TAVAB Start Date*: 2014-07-17
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB)
    Medical condition: Myasthenia Gravis Systemic Lupus Erythematosus Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002665-30 Sponsor Protocol Number: RENAISSANCE Start Date*: 2016-01-11
    Sponsor Name:Krankenhaus Nordwest gGmbH
    Full Title: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric jun...
    Medical condition: limited-metastatic adenocarcinoma of the stomach or esophagogastric junction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002096-96 Sponsor Protocol Number: NL57849.068.16 Start Date*: 2016-09-20
    Sponsor Name:Maastricht University Medical Center
    Full Title: TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia, a multicenter, open-label, non-randomized, controlled study (TOPIC-3 study)
    Medical condition: High-grade Cervical Intraepithelial Neoplasia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005127-27 Sponsor Protocol Number: CIGE025ENL01T Start Date*: 2015-05-29
    Sponsor Name:UMC Utrecht
    Full Title: Markers of Efficacy of Xolair (Omalizumab) in Chronic Spontaneous Urticaria
    Medical condition: Chronic spontaneous urticaria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004101-75 Sponsor Protocol Number: S56122-ML10190 Start Date*: 2014-03-28
    Sponsor Name:UZ Leuven
    Full Title: Randomized crossover trial to assess the effects and quality of life in patients with locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel: Q...
    Medical condition: locally advanced or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015059-26 Sponsor Protocol Number: 510460 Start Date*: 2010-08-19
    Sponsor Name:Actavis GmbH & Co. KG
    Full Title: Efficacy of 12 weeks oral Pentalong® on Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension Short title: CAESAR Clinical efficacy ...
    Medical condition: Woman and men suffering from heart failure NYHA II-IV and secondary pulmonary hypertension Objectives PVR improvement after a 12 week oral Pentalong® therapy in addition to standard long-term HF...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003068-47 Sponsor Protocol Number: UROBOTOX 1 Start Date*: 2005-09-22
    Sponsor Name:Region Skåne, Universitetssjukhuset i Lund, Urologiska kliniken
    Full Title: Behandling med botulinumtoxin vid neurogen blåsfunktionsstörning
    Medical condition: The trial addresses patients with severe symptoms of neurogenic detrusor overactivity (urgency and/or urge incontinence). Eligible are those patients who have failed conservative treatment such as ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000739-97 Sponsor Protocol Number: HIC Start Date*: 2011-05-05
    Sponsor Name:Med. Univ. Wien
    Full Title: Prospective, randomized, controlled, open-label study evaluating quality of life in patients with advanced malignant tumors with and without “add-on” homeopathy
    Medical condition: Homeopathic remedies as add on therapie in cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-002550-20 Sponsor Protocol Number: AMIRA Start Date*: 2017-07-17
    Sponsor Name:University of Ulm
    Full Title: Allogeneic microbiota-reconstitution (AMR) for the Treatment of patients with diarrhea-predominant irritable bowel Syndrome (IBS-D) - the AMIRA trial
    Medical condition: diarrhea-predominant irritable bowel syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Suspended by CA)
    Trial results: (No results available)
    EudraCT Number: 2005-000959-15 Sponsor Protocol Number: HOE901/4057 Start Date*: 2005-05-17
    Sponsor Name:sanofi-aventis
    Full Title: A multicenter clinical trial to evaluate quality of life in patients with Type 2 diabetes before and after changing therapy to a combination of insulin glargine and oral antidiabetic drugs in a rea...
    Medical condition: Patients with Type 2 diabetes inadequately controlled on a combination of highest tolerable dose of oral antidiabetic drugs (OAD) + neutral protamine hagedorn (NPH) insulin for more than 3 months
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003536-12 Sponsor Protocol Number: CIGE025B1301E1 Start Date*: 2016-02-16
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: An Extension Study to CIGE025B1301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite...
    Medical condition: Allergic Asthma
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-000179-18 Sponsor Protocol Number: RG_13-322 Start Date*: 2015-04-28
    Sponsor Name:University of Birmingham [...]
    1. University of Birmingham
    2. Birmingham Women's Hospital
    Full Title: Local Oestrogen Treatment in Postmenopausal Women Undergoing Pelvic Organ Prolapse Surgery (LOTUS) - Feasibility Study
    Medical condition: Pelvic organ prolapse
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001902-10 Sponsor Protocol Number: 2006/168 Start Date*: 2006-05-31
    Sponsor Name:Kirurgisk Forskningsafsnit, Herning Sygehus
    Full Title: Effects of caffeine on people suffering from intermittens claudication. Three double blinded, placebo-controlled cross-over studies and a follow-up study.
    Medical condition: Intermittens claudication, peripheral arterial disease (PAD) Atherosclerotic disease of the lower extremities
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000292-83 Sponsor Protocol Number: Tallisur Start Date*: 2017-08-30
    Sponsor Name:Servier Deutschland GmbH
    Full Title: Prospective, Multicenter, Open-label Phase IV trial of Trifluridine/Tipiracil to Evaluate the Health-related Quality of Life in Patients with Metastatic Colorectal Cancer
    Medical condition: Histologically or cytologically confirmed UICC stage IV carcinoma of colon or rectum with metastasis (metastatic colorectal cancer) with need for treatment due to progression
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA